Affiliation:
1. 1Wellcome Sanger Institute, Hinxton, United Kingdom.
2. 2Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Cambridge, United Kingdom.
Abstract
Summary:
Given the rarity of cancer in childhood, it should be even more uncommon for pediatric cancer survivors to develop a second, independent malignancy, yet they incur a greatly elevated risk after initial remission. In this issue of Cancer Discovery, Sánchez-Guixé and colleagues unpick the origins of second tumours in four children, and the potential role platinum-based chemotherapy may play in subsequent tumorigenesis.
See related article by Sánchez-Guixé et al., p. 953 (8).
Publisher
American Association for Cancer Research (AACR)